S.Amdt. 1298

SA 1298. Mr. BURR submitted an amendment intended to be proposed to
amendment SA 891 proposed by Mr. Schumer (for himself, Mr. Wyden, Mrs.
Murray, Mr. Brown, Mr. Peters, Mr. Cardin, Ms. Cantwell, Ms. Stabenow,
Mr. Tester, Mr. Menendez, Mr. Schatz, Mr. Carper, Mr. Leahy, and Mr.
Sanders) to the bill H.R. 1319, to provide for reconciliation pursuant
to title II of S. Con. Res. 5; which was ordered to lie on the table;
as follows:
On page 83 of the amendment, strike line 18 and all that
follows through line 12 on page 86, and insert the following:
``$10,000,000,000, to remain available through September 30,

[[Page S1361]]

2031, necessary expenses with respect to the research,
development, manufacturing, production, and purchase, at the
discretion of the Secretary, of vaccines, therapeutics,
ancillary supplies necessary for the administration of such
vaccines and therapeutics, and medical devices to prevent,
prepare for, and respond to SARS-CoV-2 or any viral variant
mutating therefrom with pandemic potential and COVID-19 or
other public health threats, of which--
``(1) $4,000,000,000 shall be for the Biomedical Advanced
Research and Development Authority to support the research,
advanced research, development, manufacturing, and
procurement of medical countermeasures, which may include
supporting, maintaining, and improving domestic manufacturing
surge capacity of medical products or platform technologies
for use during a public health emergency, pursuant to section
319L of the Public Health Service Act;
``(2) $1,500,000,000 shall be for the Strategic National
Stockpile pursuant to section 319F-2 of the Public Health
Service Act related to the procurement and maintenance of
medical products and ancillary medical supplies necessary to
respond to public health threats, which may include through
the establishment and maintenance of domestic manufacturing
surge capacity or vendor managed supply reserves;
``(3) $2,000,000,000 shall be for the National Institutes
of Health to support the research and development of medical
countermeasures, including broad-spectrum antivirals for
SARS-CoV-2;
``(4) $1,000,000,000 shall be for the Biomedical Advanced
Research and Development Authority to support the research
and development of broad-spectrum antivirals for SARS-CoV-2;
and
``(5) $1,500,000,000 shall be for the Secretary for rapid
screening, identification, and development of compounds and
platform technologies that may support preparedness for and
response to a potential public health threat.

``SEC. 2304. FUNDING FOR COVID-19 VACCINE, THERAPEUTIC, AND
DEVICE ACTIVITIES AT THE FOOD AND DRUG
ADMINISTRATION.

``In addition to amounts otherwise available, there is
appropriated to the Secretary for fiscal year 2021, out of
any money in the Treasury not otherwise appropriated,
$500,000,000, to remain available until expended, to prevent,
prepare for, and respond to COVID-19, domestically or
internationally, including the development and review of
medical countermeasures to address COVID-19 and emerging
variants of COVID-19, and which may be used for the
evaluation of the continued performance, safety, and
effectiveness, including with respect to emerging COVID-19
variants, of vaccines, therapeutics, and diagnostics
approved, cleared, licensed, or authorized for use for the
treatment, prevention, or diagnosis of COVID-19; facilitation
of advanced continuous manufacturing activities related to
production of vaccines and related materials; facilitation
and conduct of inspections related to the manufacturing of
vaccines, therapeutics, and devices delayed or cancelled for
reasons related to COVID-19, including modernizing inspection
processes; facilitation of the use of real world evidence and
real world data for approved, cleared, licensed, or
authorized medical products; review of devices authorized for
use for the treatment, prevention, or diagnosis of COVID-19;
and oversight of the supply chain and mitigation of shortages
of vaccines, therapeutics, and devices approved, cleared,
licensed, or authorized for use for the treatment,
prevention, or diagnosis of COVID-19 by the Food and Drug
Administration.

``SEC. 2305. REDUCED COST-SHARING.

``(a) In General.--Section 1402 of the Patient Protection
and Affordable Care Act is amended by redesignating
subsection (f) as subsection (g) and by inserting after
subsection (e) the following new subsection:
`` `(f) Special Rule for Individuals Who Receive
Unemployment Compensation During 2021.--For purposes of this
section, in the case of an individual who has received, or
has been approved to receive, unemployment compensation for
any week beginning during 2021, for the plan year in which
such week begins--
`` `(1) such individual shall be treated as meeting the
requirements of subsection (b)(2), and
`` `(2) for purposes of subsections (c) and (d), there
shall not be taken into account any household income of the
individual in excess of 133 percent of the poverty line for a
family of the size involved.'.
``(b) Effective Date.--The amendment made by this section
shall apply to plan years beginning after December 31, 2020.

``Subtitle E--Testing

``SEC. 2401. FUNDING FOR COVID-19 TESTING, CONTACT TRACING,
AND MITIGATION ACTIVITIES.

``(a) In General.--In addition to amounts otherwise
available, there is appropriated to the Secretary of Health
and Human Services (in this subtitle referred to as the
`Secretary') for fiscal year 2021, out of any money in the
Treasury not otherwise appropriated, $40,080,000,000, to
remain available until expended, to''.
______